Scrapie pathogenesis in subclinically infected B-cell-deficient mice. by Frigg, R et al.
University of Zurich





Scrapie pathogenesis in subclinically infected B-cell-deficient
mice
Frigg, R; Klein, M A; Hegyi, I; Zinkernagel, R M; Aguzzi, A
Frigg, R; Klein, M A; Hegyi, I; Zinkernagel, R M; Aguzzi, A. Scrapie pathogenesis in subclinically infected
B-cell-deficient mice. J. Virol. 1999, 73(11):9584-8.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Virol. 1999, 73(11):9584-8
Frigg, R; Klein, M A; Hegyi, I; Zinkernagel, R M; Aguzzi, A. Scrapie pathogenesis in subclinically infected
B-cell-deficient mice. J. Virol. 1999, 73(11):9584-8.
Postprint available at:
http://www.zora.unizh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.unizh.ch
Originally published at:
J. Virol. 1999, 73(11):9584-8
Scrapie pathogenesis in subclinically infected B-cell-deficient
mice
Abstract
Prion infections can present without clinical manifestations. B-cell deficiency may be a model for
subclinical transmissible spongiform encephalopathy, since it protects mice from disease upon
intraperitoneal administration of scrapie prions; however, a proportion of B-cell-deficient mice
accumulate protease-resistant prion protein in their brains. Here, we have characterized this subclinical




Nov. 1999, p. 9584–9588 Vol. 73, No. 11
Copyright © 1999, American Society for Microbiology. All Rights Reserved.
NOTES
Scrapie Pathogenesis in Subclinically Infected B-Cell-Deficient Mice
RICO FRIGG,1 MICHAEL A. KLEIN,1 IVAN HEGYI,1 ROLF M. ZINKERNAGEL,2
AND ADRIANO AGUZZI1*
Institutes of Neuropathology1 and Experimental Immunology,2 Department of Pathology, CH-8091 Zurich, Switzerland
Received 26 April 1999/Accepted 26 July 1999
Prion infections can present without clinical manifestations. B-cell deficiency may be a model for subclinical
transmissible spongiform encephalopathy, since it protects mice from disease upon intraperitoneal adminis-
tration of scrapie prions; however, a proportion of B-cell-deficient mice accumulate protease-resistant prion
protein in their brains. Here, we have characterized this subclinical disease. In addition, we have studied the
possibility that a neurotoxic factor secreted by B cells may contribute to pathogenesis.
Prion diseases are transmissible neurodegenerative disor-
ders of rodents, ruminants, and humans. According to the
protein-only hypothesis (21) the infectious principle is a patho-
logical isoform (termed PrPSc) of the normal, host-encoded
prion protein (termed PrPC): PrPSc is thought to replicate by
converting PrPC into further PrPSc. PrPC is necessary for prion
replication (7, 24), and differences in the amino acid sequences
of PrPC were shown to be the main determinants of interspe-
cies transmission barriers (25). Upon intracerebral (i.c.) or
peripheral exposure, replication of prion infectivity occurs in
the lymphoreticular system (LRS) of experimental animals
long before becoming detectable in the central nervous system
(CNS) (10, 12).
LRS colonization is important for the preneural phase of
scrapie pathogenesis. Peripheral inoculation of SCID (2),
RAG-12/2 (18), and RAG-22/2 (26) mice which lack mature
lymphocytes and follicular dendritic cells (FDCs), as well as
mMT mice (15) which lack mature B cells and immunoglobu-
lins, fails to establish prion replication in the LRS and does not
lead to manifest scrapie for .600 days (16). However, upon i.c.
challenge with a mouse-adapted scrapie strain, immunodefi-
cient mice succumb to scrapie similarly to wild-type controls.
SCID mice resist infection with bovine spongiform encephalitis
(BSE) even upon i.c. challenge (5). Hence, lymphocytes and
FDCs are involved in prion transfer from peripheral sites to
the CNS and in trespassing species barriers.
The brains of B-cell-deficient animals were sampled ran-
domly at late time points (222 to 504 days) after inoculation
with scrapie prions and assayed for protease-resistant PrPSc
and/or infectivity: 5 of 14 mice (13 to 65% within a confidence
interval of 95%) tested positive by either Western blot analysis,
infectivity bioassay, or both (16). However, clinically apparent
scrapie was never detected in B-cell-deficient mice (n 5 27),
even 665 days after intraperitoncal (i.p.) inoculation with pri-
ons (16), suggesting that a neurotoxic or catalytic factor se-
creted by B cells may contribute to pathogenesis and lead to
the manifestation of symptoms. If this were true, i.c. inocula-
tion of mMT or RAG-12/2 mice with inoculum derived from
mMT or RAG-22/2 brains would not contain such a hypothet-
ical cofactor and therefore should not lead to scrapie in the
recipient mice.
We therefore prepared prion inocula from brains of two
RAG-22/2 and two mMT mice which had been scrapie inocu-
lated i.p. (Table 1). Brain homogenates (1%) were prepared as
described previously (8) and inoculated i.c. into mMT and
Rag-12/2 mice, which were kept under pathogen-free condi-
tions.
One RAG-22/2 mouse and one mMT mouse contained lev-
els comparable to terminally-scrapie-sick wild-type mice, as
assayed by titration of infectivity by incubation time (22) in
PrP-overexpressing tga20 indicator mice (11). The brain infec-
tivity titer in the second RAG-22/2 mouse was approximately 2
log 50% lethal dose units lower. The second mMT mouse was
not tested for infectivity, but showed PrPSc levels exceeding the
ones of the infected wild-type control upon Western blotting
(16). For the latter, 80 mg of total protein was electrophoresed
through sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (12% polyacrylamide), transferred to nitrocellulose
membranes, probed with monoclonal antibody 6H4 (17) to
mouse PrP, and developed by enhanced chemiluminescence
(Amersham).
Sixteen mice were inoculated i.c. with prions derived from
brains of asymptomatic mMT and Rag-22/2 mice which had
been challenged i.p.: all mice developed weight loss, hind limb
paresis, ataxia, apathy, and hunched posture, with incubation
periods shown in Table 1, and were killed when terminally sick.
To confirm the diagnosis of scrapie, we investigated the accu-
mulation of PrPSc in one brain for each group of mice by
Western blot and histoblot analyses, and assessed spongiosis
and gliosis in paraffin-embedded brain sections of all mice.
PrPSc (Fig. 1) and/or transmissible spongiform encephalopa-
thy-characteristic histopathology (not shown) was demon-
strated in all brains of clinically sick mice.
We noted a statistically significant tendency towards shorter
incubation periods when compared with the incubation periods
of RAG-22/2 and mMT mice primarily inoculated i.c. with
standard Rocky Mountain Laboratory (RML) prions (Stu-
dent’s t test, P , 0.001). For example, the inoculum derived
from a mMT mouse sacrificed 436 days after i.p. inoculation
which did not display clinical symptoms provoked terminal
stage scrapie with an average of 149 days, whereas mMT mice
i.c. challenged with RML prions (derived from terminally sick
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CD1 wild-type animals) succumbed with an average of 181
days.
PrPSc was demonstrated in all brains tested by Western
blotting (Fig. 1). Glycoform ratios were calculated by densito-
metric analysis with ImageQuaNT software, and evidenced a
characteristic pattern of proteinase K-resistant un-, mono-, or
diglycosylated PrP (9), which was similar to the patterns of
RML-inoculated C57/BL6, RAG-22/2, and mMT mice (Fig. 1).
For histoblots (27), frozen sections (8 mm) were mounted on
nitrocellulose and subjected to limited proteolysis (proteinase
K at 100 mg/ml, 37°C, 4 h). Detection was accomplished with
monoclonal antibody 6H4 to PrP (17) (1:2,000) as described
previously (3). Histoblots of forebrain with cortex and basal
ganglia, rostral hippocampus with thalamus and brain stem,
and cerebellum did not reveal differences in the distribution of
proteinase K-resistant PrP in infected yet clinically healthy
immunodeficient animals compared to terminally-scrapie-sick
mMT and RAG mice inoculated i.c. with RML prions, and with
one RML-inoculated, terminally scrapie sick TcRa2/2 mouse
(20) lacking all T-cell receptor alpha/beta (TCR-a/b)-express-
ing lymphocytes (Fig. 2).
Upon formic acid inactivation (6) and paraffin embedding,
brain sections were stained with hematoxylin-eosin and with
antibodies to glial fibrillary acidic protein. Gliosis (a nonspe-
cific but early indicator of brain damage) was visualized by the
presence of large immunostained reactive astrocytes. All
scrapie-sick mice displayed characteristic vacuolar changes and
strong reactive gliosis with a regional lesion profile very similar
to that of RAG-22/2, mMT, and C57/BL6 mice inoculated i.c.
with RML prions (Fig. 3).
In a former study, we discovered that mice lacking differen-
tiated B lymphocytes can harbor high titers of prion infectivity
and PrPSc in their brains following peripheral challenge with an
RML standard inoculum, yet do not develop clinical symptoms
of scrapie. This surprising finding led us to hypothesize that
once prions have reached the CNS, a neurotoxic or catalytic
cofactor produced by B lymphocytes could be responsible for,
or at least dramatically accelerate, the decline of CNS neurons
FIG. 1. Western blot analysis of brains of immunodeficient mice challenged i.p. with RML prions and not exhibiting clinical symptoms (lanes 1 to 3) and of
immunodeficient mice challenged i.c. with inocula derived from asymptomatic RAG-22/2 and mMT mice (lanes 4 to 7). The latter mice were terminally sick. The lower
tabulation indicates the relative percent contribution of un-, mono-, and diglycosylated prion protein bands after proteinase K (PK) digestion to the total PrPSc
immunoreactivity present on the blot. The predominance of the monoglycosylated form in all mice, as well as the very similar glycoform ratio in all samples tested,
indicates that no alteration of the strain properties detectable by glycotype analysis has taken place during the passage of CD-1 mouse-derived RML prions onto
RAG-22/2 and mMT mice (genetic background, C57/BL6), and upon a second passage onto further RAG-12/2 and mMT mice. Lane 8, brain of a terminally scrapie
sick C57/BL6 mouse inoculated with RML prions; lanes 9 and 10, brain of a noninfected C57/BL6 mouse, showing no anti-PrP immunoreactive bands upon treatment
with proteinase K; lane 11, brain of a Prnp0/0 mouse.
TABLE 1. Origin of scrapie inoculum, occurrence of clinical
scrapie, and latency of disease in immunodeficient mice inoculated






period (days) 6 SD
RAG-22/2
Day 286 RAG-12/2 182 6 35
Day 342 155 6 2.2
mMT
Day 375 mMT 161 6 5.5
Day 432 149 6 9.4
a Note that in each group, four of four mice developed scrapie.
b One percent brain homogenate.
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and lead to the manifestation of symptoms in concert with the
infectious agent. There are examples for similar pathogenetic
mechanisms: in human immunodeficiency virus infection of the
CNS, for example, pathogenesis is mediated not only by viral
products (28), but also by nitric oxide produced by infected
microglial cells (13).
Because B-cell-deficient mice develop scrapie upon i.c. in-
fection with a standard RML inoculum with the same latency
and efficiency as wild-type control mice (16), a possible neu-
rotoxic cofactor would have to be present in infectious brain
homogenates derived from immunocompetent animals. If so,
i.c. inoculation of B-cell-deficient mice with an inoculum de-
rived from brains of subclinically infected B-cell-deficient mice
should result in greatly (or indefinitely) prolonged incubation
times, since the primary i.p. inoculation of B-cell-deficient
mice would dilute the cofactor.
However, the results of the present study confirm that B
lymphocytes and their secreted products do not influence
scrapie pathogenesis if the agent is directly inoculated into the
brain. This remains true even after prions have been passaged
twice in B-cell-deficient mice. We can also exclude the involve-
ment a cofactor produced by T lymphocytes, which are known
to be able to invade CNS parenchyma when activated (4, 19),
since RAG-12/2 and RAG-22/2 mice are devoid of both B and
T cells.
We have considered the possibility that the agent may have
undergone a “strain shift” changing its pathogenic properties
(1), because it was passaged twice in immunodeficient hosts
and it induced disease with shortened incubation times upon
its second passage. However, this is very unlikely since (i) the
glycoform distribution of PrPSc, (ii) the regional patterns of
PrPSc deposition as assessed by histoblotting, and (iii) the
lesion profiles in the brains of RAG-12/2 and mMT mice in-
oculated with prions from immunodeficient mice are indis-
tinguishable from those of RML-inoculated TcRa2/2, RML-
inoculated RAG-22/2, mMT, and wild-type mice.
While it is remarkable that immunodeficient mice harboring
brain infectivity titers equaling or even exceeding those of
terminally sick wild-type controls can be perfectly healthy on
clinical examination, there are further documented examples
of chronic subclinical infections with prions. Mice heterozy-
gous for a disrupted PrP gene show high prion and PrPSc levels,
but a delayed onset of disease (7). Hamster prions can persist
and perhaps even replicate in a clinically silent fashion when
transmitted to mice (23). In the latter experiment, mice inoc-
ulated with hamster prions clinically resisted infection, yet
when brain homogenates of these mice were transmitted to
further animals, hamsters (but not mice) developed scrapie.
However, subclinical infection may also occur when prions
are being passaged within the same species. Although many
FIG. 2. Histoblot analysis of distribution patterns of proteinase K (PK)-resistant PrPSc in different brain regions of immunodeficient mice. Coronal sections through
the forebrain including the basal ganglia (rows 1 and 2), through the rostral hippocampus and thalami (rows 3 and 4), and through the caudal regions including brain
stem and cerebellum (rows 5 and 6) show indistinguishable patterns of PrPSc distributions in RAG-22/2 and mMT mice inoculated i.c. with RML prions (columns 1
and 3, respectively) and in RAG-12/2 and mMT mice inoculated i.c. with inocula derived from asymptomatic RAG-22/2 and mMT mice (columns 2 and 4, respectively),
as well as in TCRa2/2 mice succumbing from scrapie upon i.c. inoculation with RML prions (column 5). 375d and 342d, days of inoculation.
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patients were presumably exposed to Creutzfeldt-Jakob dis-
ease-contaminated batches of growth hormone and gonado-
tropins, only about 100 (14) developed overt disease. This may
be interpreted as a sign that the “take” of infection occurred
only in few individuals, perhaps because the inoculum was
small, or that incubation times vary vastly so that many indi-
viduals may have developed subclinical infection.
Also the fact that only single cows developed clinically overt
BSE in exposed herds raises the possibility that subclinical
infection of cattle with BSE may occur more frequently than
suspected. Given the health hazards posed by BSE, the phe-
nomenon of subclinical prion infections deserves in-depth in-
vestigations: B-cell-deficient mice may serve as a suitable
model system. The results presented here argue against a di-
rect effect of B lymphocytes or their secreted products on
establishment of subclinical prion infection and raise the pos-
sibility that secondary events, such as maturation of cells in-
duced by B lymphocytes—e.g., FDCs in lymphoid organs or
immune cells resident in the CNS—may contribute to scrapie
neurotoxicity.
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